Nyxoah (NASDAQ:NYXH – Get Free Report) and DIH Holding US (NASDAQ:DHAI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.
Profitability
This table compares Nyxoah and DIH Holding US’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -1,043.93% | -51.68% | -40.11% |
| DIH Holding US | -13.59% | -5.07% | -25.97% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Nyxoah and DIH Holding US, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 0 | 0 | 4 | 0 | 3.00 |
| DIH Holding US | 0 | 0 | 0 | 0 | 0.00 |
Risk and Volatility
Nyxoah has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, DIH Holding US has a beta of -0.56, meaning that its stock price is 156% less volatile than the S&P 500.
Institutional & Insider Ownership
27.8% of DIH Holding US shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 49.6% of DIH Holding US shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Nyxoah and DIH Holding US”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $5.08 million | 67.09 | -$46.77 million | ($1.87) | -5.35 |
| DIH Holding US | $64.47 million | 0.29 | -$8.44 million | ($0.30) | -1.31 |
DIH Holding US has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than DIH Holding US, indicating that it is currently the more affordable of the two stocks.
Summary
DIH Holding US beats Nyxoah on 9 of the 14 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About DIH Holding US
DIH Holding US, Inc. operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement. The company also provides lower extremity products, including Erigo for gradual verticalization, leg mobilization, and intensive sensorimotor stimulation through cyclic leg loading; Lokomat, a robot-assisted therapy that enables training to increase the strength of muscles and a range of motion of joints in order to improve walking; Andago, a robotics smart control system that assists patients in walking naturally; C-Mill, creates a training environment; CAREN, a computer assisted rehabilitation environment; and GRAIL, an gait real-time analysis interactive lab solution for analysis training and research. In addition, it offers SafeGait, RYSEN, and M-Gait for gait and balance; and HocoNet and D-Flow software. DIH Holding US, Inc. was founded in 2021 and is based in Norwell, Massachusetts.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
